

**Commissioning Statement:**

<p><b>Condition or Treatment:</b></p>	<p>Lycra dynamic splinting for children with neurological impairment</p>
<p><b>Commissioning position:</b></p>	<p>Requests for funding will only be considered on an individual patient basis by the CCG IFR Panel.</p> <p>The referral needs to come from a local lead specialist physiotherapist or occupational therapist. The expected benefits for that patient over other treatments must be clearly quantified.</p> <p>Expert opinion suggests that younger children with athetoid disorders (involuntary movements), those with quadriplegic palsy and those with neuromuscular disorders benefit the most.</p> <p>Lycra dynamic splinting is not suitable for clients who have fixed deformities of a bony nature which are not amenable to change.</p> <p>Compliance has a significant role to play in determining outcome, as it does for all therapy and medical interventions. The client and family or carers, who may be assisting them to apply the splints, are made fully aware of the commitment required to ensure success.</p> <p>Provision of subsequent garments will depend on clear, quantifiable demonstration of benefit for the individual patient which has been set upfront.</p> <p>Patients who are not eligible for treatment under this policy may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. Individual cases will be reviewed as per the CCG policy.</p> <p>Investigations prior to referral</p> <ul style="list-style-type: none"> <li>• None</li> </ul>
<p><b>Referral Guidance:</b></p>	<p>The referral letter should contain:</p> <ul style="list-style-type: none"> <li>• Details of how the patient meets the above criteria OR demonstrates clinical exceptionality</li> <li>• Impact on activities of daily living</li> <li>• Treatments and interventions tried including the results</li> <li>• Drug history (prescribed and non-prescribed)</li> <li>• Relevant past medical/surgical history</li> <li>• Current regular medication</li> <li>• BMI</li> </ul> <p>Exceptional cases can be referred to the CCG's Individual Funding Request Panel for prior approval.</p> <ul style="list-style-type: none"> <li>• HRW/SR GP Practices: <a href="https://ifryh.necsu.nhs.uk/">https://ifryh.necsu.nhs.uk/</a></li> <li>• HaRD GP practices: <a href="#">Referral Form</a></li> </ul>



<b>Effective From:</b>	1 July 2021
<b>Date:</b>	April 2020
<b>Review Date:</b>	July 2023
<b>Clinical Author:</b>	Dr Emma O'Neill, Clinical Advisor North Yorkshire CCG

**Additional Information/References:**